Delstrigo
·
- Prescription status not stated
- Antibiotics, antivirals and antifungals taken into the body
- Active substance
- Doravirine;lamivudine;tenofovir disoproxil
- Made by
- Merck Sharp & Dohme B.V.
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Delstrigo is indicated for the treatment of adults infected with HIV 1 without past or present evidence of resistance to the NNRTI class, lamivudine, or tenofovir. Delstrigo is also indicated for the treatment of adolescents aged 12 years and older weighing at least 35 kg who are infected with HIV-1 without past or present evidence of resistance to the NNRTI class, lamivudine, or tenofovir and who have experienced toxicities which preclude the use of other regimens that do not contain tenofovir disoproxil.
From the official label · 2026-09-30 · European Medicines Agency
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
CanadaNo exact match for this strength and form
Details
| Made by | Merck Sharp & Dohme B.V. |
|---|---|
| Active substance | Doravirine;lamivudine;tenofovir disoproxil |
| Used in | Antibiotics, antivirals and antifungals taken into the body |
| Classification | J05AR · Antibiotics, antivirals and antifungals taken into the body |
| Authorised on | 2018-11-22 |
| Last updated by the regulator | 2025-12-03 |
| EMA product number | EMEA/H/C/004746 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).